[{"address1": "101 Lindenwood Drive", "address2": "Suite 225", "city": "Malvern", "state": "PA", "zip": "19355", "country": "United States", "phone": "(484) 875-3192", "website": "https://www.annovisbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.", "fullTimeEmployees": 6, "companyOfficers": [{"maxAge": 1, "name": "Mr. Mark K. White", "age": 67, "title": "Chief Business Officer & Director", "yearBorn": 1956, "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 4.4, "open": 4.46, "dayLow": 4.31, "dayHigh": 4.53, "regularMarketPreviousClose": 4.4, "regularMarketOpen": 4.46, "regularMarketDayLow": 4.31, "regularMarketDayHigh": 4.53, "forwardPE": -5.0229883, "volume": 329981, "regularMarketVolume": 329981, "averageVolume": 280598, "averageVolume10days": 347580, "averageDailyVolume10Day": 347580, "bid": 4.15, "ask": 4.35, "bidSize": 1200, "askSize": 800, "marketCap": 60293764, "fiftyTwoWeekLow": 4.3, "fiftyTwoWeekHigh": 22.49, "fiftyDayAverage": 7.3578, "twoHundredDayAverage": 8.4902, "currency": "USD", "enterpriseValue": 47657316, "floatShares": 10822005, "sharesOutstanding": 13797200, "sharesShort": 1311926, "sharesShortPriorMonth": 1399763, "sharesShortPreviousMonthDate": 1730332800, "dateShortInterest": 1732838400, "sharesPercentSharesOut": 0.0951, "heldPercentInsiders": 0.20402001, "heldPercentInstitutions": 0.08834, "shortRatio": 6.21, "shortPercentOfFloat": 0.1195, "impliedSharesOutstanding": 13797200, "bookValue": 0.532, "priceToBook": 8.214286, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -40939112, "trailingEps": -4.22, "forwardEps": -1.81, "52WeekChange": -0.71530944, "SandP52WeekChange": 0.2421279, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "ANVS", "underlyingSymbol": "ANVS", "shortName": "Annovis Bio, Inc.", "longName": "Annovis Bio, Inc.", "firstTradeDateEpochUtc": 1580308200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "e153bc75-9830-375d-bf5e-330db4df878a", "messageBoardId": "finmb_622711087", "gmtOffSetMilliseconds": -18000000, "currentPrice": 4.37, "targetHighPrice": 72.0, "targetLowPrice": 21.0, "targetMeanPrice": 34.8, "targetMedianPrice": 26.0, "recommendationMean": 1.66667, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 12636630, "totalCashPerShare": 0.916, "quickRatio": 2.344, "currentRatio": 2.664, "returnOnAssets": -1.5458, "returnOnEquity": -5.9669704, "freeCashflow": -11572214, "operatingCashflow": -22974234, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-21"}]